


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:38Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12404901" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12404901</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" id="jne70066" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neuroendocrinol</journal-id><journal-id journal-id-type="iso-abbrev">J Neuroendocrinol</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">JNE</journal-id><journal-title-group><journal-title>Journal of Neuroendocrinology</journal-title></journal-title-group><issn pub-type="ppub">0953-8194</issn><issn pub-type="epub">1365-2826</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12404901</article-id><article-id pub-id-type="pmcid-ver">PMC12404901.1</article-id><article-id pub-id-type="pmcaid">12404901</article-id><article-id pub-id-type="pmcaiid">12404901</article-id><article-id pub-id-type="pmid">40765079</article-id><article-id pub-id-type="doi">10.1111/jne.70066</article-id><article-id pub-id-type="publisher-id">JNE70066</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Translational and Clinical Neuroendocrinology</subject></subj-group></article-categories><title-group><article-title>Prolactin&#8208;adjusted inferior petrosal sinus sampling: Pituitary and ectopic adrenocorticotropic hormone&#8208;dependent Cushing syndrome</article-title><alt-title alt-title-type="left-running-head">Sprenkeler et al.</alt-title></title-group><contrib-group><contrib id="jne70066-cr-0001" contrib-type="author"><name name-style="western"><surname>Sprenkeler</surname><given-names initials="VE">Vera E.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0008-8538-9495</contrib-id><xref rid="jne70066-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jne70066-cr-0002" contrib-type="author"><name name-style="western"><surname>van Herwaarden</surname><given-names initials="AE">Antonius E.</given-names></name><xref rid="jne70066-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jne70066-cr-0003" contrib-type="author"><name name-style="western"><surname>van de Ven</surname><given-names initials="AC">Annenienke C.</given-names></name><xref rid="jne70066-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jne70066-cr-0004" contrib-type="author"><name name-style="western"><surname>Kusters</surname><given-names initials="B">Benno</given-names></name><xref rid="jne70066-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jne70066-cr-0005" contrib-type="author"><name name-style="western"><surname>Jenniskens</surname><given-names initials="SFM">Sjoerd F. M.</given-names></name><xref rid="jne70066-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="jne70066-cr-0006" contrib-type="author"><name name-style="western"><surname>Netea&#8208;Maier</surname><given-names initials="RT">Romana T.</given-names></name><xref rid="jne70066-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jne70066-cr-0007" contrib-type="author" corresp="yes"><name name-style="western"><surname>de Laat</surname><given-names initials="JM">Joanne M.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3316-1540</contrib-id><xref rid="jne70066-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>marieke.delaat@radboudumc.nl</email></address></contrib></contrib-group><aff id="jne70066-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Internal Medicine, Division of Endocrinology</named-content>
<institution>Radboud University Medical Center</institution>
<city>Nijmegen</city>
<country country="NL">The Netherlands</country>
</aff><aff id="jne70066-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Laboratory Medicine</named-content>
<institution>Radboud University Medical Center</institution>
<city>Nijmegen</city>
<country country="NL">The Netherlands</country>
</aff><aff id="jne70066-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Radboud University Medical Center</institution>
<city>Nijmegen</city>
<country country="NL">The Netherlands</country>
</aff><aff id="jne70066-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Medical Imaging</named-content>
<institution>Radboud University Medical Center</institution>
<city>Nijmegen</city>
<country country="NL">The Netherlands</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Joanne M. De Laat, RadboudUMC, Department of Internal Medicine, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.<break/>
Email: <email>marieke.delaat@radboudumc.nl</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2025</year></pub-date><volume>37</volume><issue seq="130">9</issue><issue-id pub-id-type="pmc-issue-id">496084</issue-id><issue-id pub-id-type="doi">10.1111/jne.v37.9</issue-id><elocation-id>e70066</elocation-id><history><date date-type="rev-recd"><day>14</day><month>5</month><year>2025</year></date><date date-type="received"><day>12</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Journal of Neuroendocrinology</italic> published by John Wiley &amp; Sons Ltd on behalf of British Society for Neuroendocrinology.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="JNE-37-e70066.pdf"/><self-uri content-type="pdf" xlink:href="file:JNE-37-e70066.pdf"/><abstract><title>Abstract</title><p>Inferior petrosal sinus sampling (IPSS) is a diagnostic procedure used to differentiate between ectopic adrenocorticotropic hormone (ACTH)&#8208;dependent Cushing syndrome (EAS) and pituitary ACTH&#8208;dependent Cushing syndrome (CD). This study investigated the diagnostic value of IPSS, focusing on the use of prolactin adjustments and different calculation methods. We retrospectively analyzed data from patients with ACTH&#8208;dependent Cushing syndrome and inconclusive pituitary&#8208;MRI who underwent IPSS with corticotropin&#8208;releasing hormone (CRH) stimulation between 2015 and 2025. The cohort included 19 patients (16 CD, 3 EAS), with diagnoses confirmed by pathology examination and/or biochemical remission 1&#8201;year post&#8208;surgery. A pituitary source was confirmed in all patients with CD (<italic toggle="no">n</italic>&#8201;=&#8201;16) through pathology and/or biochemical remission. An ectopic source was confirmed by pathology in two of three patients with EAS. Using unadjusted ACTH ratios and previously established cut&#8208;off values resulted in three incorrect diagnoses out of 20 procedures. In contrast, prolactin&#8208;adjusted peak ACTH ratios provided a more distinct separation between CD and EAS, enabling correct diagnosis in all cases. Optimal cut&#8208;off values determined by receiver operating characteristic curve analysis were 1.0 for basal and 1.7 for concurrent prolactin&#8208;adjusted peak ACTH ratios, yielding 100% sensitivity and specificity. Basal prolactin&#8208;adjusted peak ACTH ratios were &gt;1.5 in all patients with CD and&#8201;&lt;0.6 in all patients with EAS, while concurrent ratios were&#8201;&gt;1.1 in all patients with CD and&#8201;&lt;0.3 in all patients with EAS. Prolactin&#8208;adjusted peak ACTH ratios improve the diagnostic accuracy of IPSS and can effectively differentiate between ectopic and pituitary sources of ACTH. This study enhances the diagnostic accuracy of inferior petrosal sinus sampling (IPSS) for differentiating pituitary from ectopic ACTH&#8208;dependent Cushing syndrome by incorporating prolactin measurements and exploring various calculation methods. The findings contribute to advancing diagnostic techniques and improving clinical management of endocrine disorders. By enabling more accurate identification of the underlying cause of ACTH&#8208;dependent Cushing syndrome, this work supports clinicians in selecting optimal treatment strategies.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jne70066-kwd-0001">ACTH hypersecretion</kwd><kwd id="jne70066-kwd-0002">petrosal sinus sampling</kwd><kwd id="jne70066-kwd-0003">prolactin adjustment</kwd></kwd-group><counts><fig-count count="4"/><table-count count="2"/><page-count count="12"/><word-count count="7200"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.2 mode:remove_FC converted:02.09.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jne70066-cit-9001"><string-name name-style="western"><surname>Sprenkeler</surname><given-names>VE</given-names></string-name>, <string-name name-style="western"><surname>van Herwaarden</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>van de Ven</surname><given-names>AC</given-names></string-name>, et al. <article-title>Prolactin&#8208;adjusted inferior petrosal sinus sampling: Pituitary and ectopic adrenocorticotropic hormone&#8208;dependent Cushing syndrome</article-title>. <source>J Neuroendocrinol</source>. <year>2025</year>;<volume>37</volume>(<issue>9</issue>):<elocation-id>e70066</elocation-id>. doi:<pub-id pub-id-type="doi">10.1111/jne.70066</pub-id><pub-id pub-id-type="pmid">40765079</pub-id><pub-id pub-id-type="pmcid">PMC12404901</pub-id></mixed-citation>
</p></notes></front><body id="jne70066-body-0001"><sec id="jne70066-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Cushing syndrome comprises a large set of symptoms that reflect prolonged and inappropriately high exposure to glucocorticoids. Non&#8208;iatrogenic Cushing syndrome is uncommon, with an estimated incidence of 0.2&#8211;5 million per year. The overproduction of cortisol may be due to an excess of adrenocorticotropic hormone (ACTH) secretion or by autonomous adrenal overproduction.<xref rid="jne70066-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> ACTH&#8208;dependent hypercortisolism is typically due to a pituitary source (80%&#8211;85%) or, less commonly, an ectopic source (10%&#8211;20%).<xref rid="jne70066-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="jne70066-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Differentiating between pituitary and ectopic ACTH secretion is crucial for determining appropriate treatment, such as transsphenoidal resection of a pituitary tumor or resection of an ectopic tumor. This distinction is particularly challenging when a pituitary microadenoma is not clearly visible on MRI.<xref rid="jne70066-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</p><p>Inferior petrosal sinus sampling (IPSS) is used to distinguish pituitary ACTH&#8208;dependent Cushing disease (CD) from ectopic ACTH&#8208;dependent syndrome (EAS) after ACTH&#8208;dependent hypercortisolism is confirmed biochemically and no adenoma or an adenoma &lt;6&#8201;mm is detected on MRI.<xref rid="jne70066-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="jne70066-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="jne70066-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="jne70066-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> According to updated guidelines by Fleseriu et al., management of adenomas 6&#8211;9&#8201;mm remains debated, with some recommending IPSS for adenomas &lt;10&#8201;mm.<xref rid="jne70066-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> An (unadjusted) petrosal sinus&#8208;to&#8208;peripheral ACTH ratio&#8201;&#8805;2.0 at baseline or &#8805;3.0 post&#8208;corticotropin&#8208;releasing hormone (CRH) administration indicates a pituitary source, while lower ratios suggest an ectopic source.<xref rid="jne70066-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="jne70066-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> However, these cut&#8208;off values are based on limited studies with small cohorts,<xref rid="jne70066-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="jne70066-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="jne70066-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="jne70066-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="jne70066-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="jne70066-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> and their generalizability is uncertain. Factors such as fluctuations in ACTH secretion, catheter placement relative to the ACTH source, and variable venous efflux can affect ACTH concentrations and calculated ratios.<xref rid="jne70066-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="jne70066-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="jne70066-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="jne70066-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="jne70066-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Consequently, IPSS should ideally be standardized and performed in experienced centers to minimize variability. Reported false&#8208;negativity rates for IPSS range from 1% to 12%.<xref rid="jne70066-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="jne70066-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="jne70066-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>
</p><p>To mitigate these limitations, prolactin measurements have been proposed to enhance IPSS outcomes. Recent studies suggest that prolactin&#8208;adjusted ACTH ratios improve diagnostic accuracy,<xref rid="jne70066-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="jne70066-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="jne70066-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="jne70066-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="jne70066-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="jne70066-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="jne70066-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> though different adjustment methods and cut&#8208;off values have been used.<xref rid="jne70066-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="jne70066-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="jne70066-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="jne70066-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>
</p><p>Prolactin may help normalize variability in catheter placement and venous efflux, potentially improving IPSS diagnostic accuracy. However, the performance of various prolactin adjustment methods in real&#8208;life clinical practice remains unclear.<xref rid="jne70066-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="jne70066-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> The aim of this study is to evaluate whether the use of prolactin ratios improves IPSS accuracy in clinical practice at a center of expertise for pituitary tumors, by comparing different prolactin adjustment methods.</p></sec><sec sec-type="methods" id="jne70066-sec-0002"><label>2</label><title>METHODS</title><sec id="jne70066-sec-0003"><label>2.1</label><title>Participants</title><p>We retrospectively collected data of all patients with ACTH&#8208;dependent Cushing syndrome who underwent IPSS at Radboud University Medical Center between 2015 and 2025 (<italic toggle="yes">n</italic>&#8201;=&#8201;32). Patients lost to follow&#8208;up (<italic toggle="yes">n</italic>&#8201;=&#8201;3) and those who underwent stimulation with desmopressin (DDAVP) instead of CRH (<italic toggle="yes">n</italic>&#8201;=&#8201;10) were excluded from the main analysis. One patient underwent IPSS twice, resulting in 20 IPSS procedures for the main analysis. Six DDAVP&#8208;stimulated IPSS procedures were included in an additional analysis; four other DDAVP&#8208;stimulated procedures were excluded due to follow&#8208;up &lt;1&#8201;year or pending surgery. Diagnosis of Cushing syndrome was based on clinical symptoms and biochemical tests, including lack of suppression of fasting morning cortisol (&gt;0.05&#8201;&#956;mol/L) after a 1&#8201;mg dexamethasone test, elevated 24&#8208;h urinary free cortisol, and increased midnight salivary cortisol.<xref rid="jne70066-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> All included patients had inconclusive pituitary&#8208;MRI findings, showing no adenoma (<italic toggle="yes">n</italic>&#8201;=&#8201;11) or adenomas &lt;6&#8201;mm (<italic toggle="yes">n</italic>&#8201;=&#8201;8). Ethical approval from our institutional research board (METC Oost&#8208;Nederland: 2022&#8208;13758) was obtained before the start and this study was conducted in accordance with the Helsinki Declaration. Informed consent was obtained per RadboudUMC guidelines for research using previously collected clinical data and materials.</p></sec><sec id="jne70066-sec-0004"><label>2.2</label><title>
<styled-content style="fixed-case" toggle="no">MRI</styled-content> protocol</title><p>Pituitary&#8208;MR imaging was performed on a 3&#8208;Tesla clinical MR imaging system, Magnetom Skyra; Siemens Healthineers, Erlangen, Germany. Standardized pituitary&#8208;MRI protocol consisted of T1&#8208;tse&#8208;sagital, T1&#8208;se&#8208;coronal&#8208;bloodsuppression, and T2&#8208;tse&#8208;coronal images. Post&#8208;contrast (Dotarem: 0.2&#8201;mL/kg, max. 15&#8201;mL, flow 2.5&#8201;mL/s): T1&#8208;Vibe&#8208;coronal&#8208;dynamic, T1&#8208;tse&#8208;sagital, and T1&#8208;se&#8208;coronal&#8208;bloodsuppression images. Slice thickness was 3.0&#8201;mm for T1&#8208;tse&#8208;sagital, 3.05&#8201;mm for T1&#8208;tse&#8208;sagital post contrast, and 2.0&#8201;mm for all other described images.</p></sec><sec id="jne70066-sec-0005"><label>2.3</label><title>
<styled-content style="fixed-case" toggle="no">IPSS</styled-content> procedure</title><p>Bilateral simultaneous catheterization of the inferior petrosal sinuses was performed, confirmed by venous angiography. Blood samples included a sample from both petrosal sinuses (referred to as the left and right ACTH values) and peripheral blood samples obtained from the left or right femoral vein. Samples were obtained 5&#8201;min prior (&#8722;5&#8201;min) and just before (<italic toggle="yes">t</italic>
<sub>0</sub>) CRH was administered. After administering 100&#8201;&#956;g CRH at <italic toggle="yes">t</italic>
<sub>0</sub>, samples were collected at +1&#189;, +5, +10, +15, and +20&#8201;min<xref rid="jne70066-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> (Figure&#160;<xref rid="jne70066-fig-0001" ref-type="fig">1</xref>). ACTH values were measured immediately post&#8208;procedure, and samples were stored at &#8722;30&#176;C until prolactin was analyzed.</p><fig position="float" fig-type="FIGURE" id="jne70066-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>During IPSS, blood samples are obtained simultaneously from the left inferior petrosal sinus, right inferior petrosal sinus, and femoral vein at the following time points: &#8722;5&#8201;min, <italic toggle="yes">t</italic>
<sub>0</sub>, +1&#189;&#8201;min, +5&#8201;min, +10&#8201;min, +15&#8201;min, and&#8201;+20&#8201;min.</p></caption><graphic position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="JNE-37-e70066-g002.jpg"/></fig></sec><sec id="jne70066-sec-0006"><label>2.4</label><title>Hormone assays</title><p>ACTH and prolactin values were measured using an electrochemiluminescence immunoassay (ECLIA), measured on a COBAS E801 random&#8208;access analyzer (Roche Diagnostics GmbH, Mannheim, Germany). The ACTH measuring range was 0.33&#8211;440&#8201;pmol/L, and the prolactin measuring range was 2&#8211;10,000 &#956;IU/mL. The within&#8208;laboratory coefficient of variation is 4.6% at 2.2&#8201;pmol/L and 2.5% at 22&#8201;pmol/L for ACTH and 3.0% at 160 &#956;IU/mL and 3.0% at 880 &#956;IU/mL for prolactin.</p></sec><sec id="jne70066-sec-0007"><label>2.5</label><title>Interpreting <styled-content style="fixed-case" toggle="no">IPSS</styled-content>
</title><p>ACTH ratios were calculated as the petrosal sinus ACTH value divided by the concurrent peripheral ACTH value (Figure&#160;<xref rid="jne70066-fig-0001" ref-type="fig">1</xref>: ACTH&#8208;L/ACTH&#8208;P and ACTH&#8208;R/ACTH&#8208;P). The highest ratio across all time points, pre&#8208; or post&#8208;CRH, was the peak ACTH ratio. A ratio&#8201;&#8805;2.0 pre&#8208;CRH or &#8805;3.0 post&#8208;CRH indicated CD.<xref rid="jne70066-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>
</p><p>For the prolactin&#8208;adjusted ACTH ratios, first the prolactin ratios for both the left and right sides were calculated by dividing the left and right prolactin values by the concurrent peripheral prolactin value (Figure&#160;<xref rid="jne70066-fig-0001" ref-type="fig">1</xref>: prolactin&#8208;L/prolactin&#8208;P and prolactin&#8208;R/prolactin&#8208;P).</p><p>Prolactin adjustment was performed using two previously reported methods<xref rid="jne70066-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="jne70066-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>:<list list-type="simple" id="jne70066-list-0001"><list-item id="jne70066-li-0001"><p>Method 1. Basal prolactin&#8208;adjusted peak ACTH ratio&#8201;=&#8201;(peak post&#8208;CRH<sup>a</sup> ACTH ratio)/(ipsilateral basal[<italic toggle="yes">t</italic>
<sub>0</sub>] prolactin ratio)</p></list-item><list-item id="jne70066-li-0002"><p>Method 2. Concurrent prolactin&#8208;adjusted peak ACTH ratio&#8201;=&#8201;(peak<sup>b</sup> ACTH ratio)/(ipsilateral concurrent prolactin ratio)</p></list-item></list>
<list list-type="alpha-lower" id="jne70066-list-0002"><list-item id="jne70066-li-0003"><p>Highest achieved ratio among all post&#8208;CRH time points during the procedure.</p></list-item><list-item id="jne70066-li-0004"><p>Highest achieved ratio among all time points during the procedure.</p></list-item></list>
</p><p>Hypothetically, the response of ACTH and prolactin on CRH stimulation may vary across time points. To investigate whether including non&#8208;peak ACTH ratio calculations could improve the diagnostic value compared with adjusting only the peak ACTH ratio (Methods 1 and 2), we included two other calculation methods (Methods 3 and 4). Prolactin adjustments were made according to the formulas below for each 14 ACTH ratios &#8212;corresponding to the seven left and seven right sampling time points &#8212; after which the highest prolactin&#8208;adjusted ACTH ratio was used for diagnosis. A detailed overview of the calculation Methods 1&#8211;4 has been added as Data&#160;<xref rid="jne70066-supitem-0001" ref-type="supplementary-material">S1</xref>.<list list-type="simple" id="jne70066-list-0003"><list-item id="jne70066-li-0005"><p>Method 3. Basal prolactin&#8208;adjusted ACTH ratio at <italic toggle="yes">specific time point and side</italic>&#8201;=&#8201;ACTH ratio at <italic toggle="yes">specific time point</italic>
<sup>
<italic toggle="yes">a</italic>
</sup>
<italic toggle="yes">and side</italic>
<sup>
<italic toggle="yes">b</italic>
</sup>/ipsilateral basal prolactin ratio</p></list-item><list-item id="jne70066-li-0006"><p>Method 4. Concurrent prolactin&#8208;adjusted ACTH ratio at <italic toggle="yes">specific time point and side</italic>&#8201;=&#8201;ACTH ratio at <italic toggle="yes">specific time point</italic>
<sup>
<italic toggle="yes">a</italic>
</sup>
<italic toggle="yes">and side</italic>
<sup>
<italic toggle="yes">b</italic>
</sup>/ipsilateral concurrent prolactin ratio</p></list-item></list>
<list list-type="alpha-lower" id="jne70066-list-0004"><list-item id="jne70066-li-0007"><p>ACTH values obtained at <italic toggle="yes">t</italic> &#8722; 5&#8201;min, <italic toggle="yes">t</italic>
<sub>0</sub>, +1&#189;&#8201;min, +5&#8201;min, +10&#8201;min, +15&#8201;min, or&#8201;+20&#8201;min were used.</p></list-item><list-item id="jne70066-li-0008"><p>ACTH values obtained from the left or right petrosal sinuses were used.</p></list-item></list>
</p></sec><sec id="jne70066-sec-0008"><label>2.6</label><title>Confirmation of the diagnosis</title><p>CD was confirmed by pathology of adenomatous tissue or biochemical remission 1&#8201;year post&#8208;surgery, defined as negative 1&#8201;mg dexamethasone suppression test (cortisol in serum the morning after dexamethasone &lt;0.05&#8201;&#956;mol/L), low late&#8208;night salivary cortisol, and/or morning serum cortisol &lt;0.06&#8201;&#956;mol/L.<xref rid="jne70066-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="jne70066-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> EAS was confirmed by pathology of a neuroendocrine tumor or biochemical remission, alongside pituitary&#8208;MRI without a lesion.</p></sec><sec id="jne70066-sec-0009"><label>2.7</label><title>Statistics</title><p>Continuous and categorical variables were described as mean&#8201;&#177;&#8201;standard deviation (SD) and percentages. Fisher's exact tests were used to check for confounding by variables. The following subgroups were analyzed: male versus female, &#8804;50 and &gt;50&#8201;years of age, and blood sample collection date &#8804;30 and &gt;30&#8201;months. The median age and the median blood sample collection date were used to obtain subgroups of equal size for both variables. A <italic toggle="yes">p</italic>&#8208;value &lt;.05 was considered statistically significant. Optimal cut&#8208;off values were obtained from receiver operating characteristic (ROC) curve analysis.</p></sec><sec id="jne70066-sec-0010"><label>2.8</label><title>Literature search</title><p>A literature search of the PubMed database was conducted to identify studies involving prolactin measurement adjustments in IPSS. The following search terms were used: Cushing syndrome, ACTH hypersecretion, hypercortisolism, prolactin, and inferior petrosal sinus sampling. Publications up to January 2025 were considered. Articles reporting both unadjusted ACTH ratios and prolactin&#8208;adjusted ACTH ratios were included to enable the construction of a contingency table, for example, true positives (TP), false positives (FP), false negatives (FN), and true negatives (TN). No restrictions were made based on sample size.</p></sec></sec><sec sec-type="results" id="jne70066-sec-0011"><label>3</label><title>RESULTS</title><sec id="jne70066-sec-0012"><label>3.1</label><title>Patients' characteristics</title><p>Of the 19 patients included, 16 had a pathology and/or remission&#8208;confirmed CD (age 44&#8201;&#177;&#8201;16 (SD) years, 12 women). All 16 patients underwent pituitary surgery; 8 were confirmed by both pathology and remission, 3 were confirmed by only pathology, and 5 were confirmed by only remission. Three patients had EAS (age 65&#8201;&#177;&#8201;3 (SD) years, two women). Two EAS cases had histologically confirmed ACTH&#8208;producing neuroendocrine lung tumors, and one had an unknown source (case 18). Patient characteristics are summarized in Table&#160;<xref rid="jne70066-tbl-0001" ref-type="table">1</xref>. Peripheral prolactin levels documented before IPSS were available for 17 out of 19 patients and excluded a state of hyperprolactinemia in all but one patient. Fisher's exact tests showed no confounding by variables. Blood samples required for IPSS were obtained in 17/20 (85%) procedures; two had only right&#8208;sided results, and one had a missing right&#8208;sided value.</p><table-wrap position="float" id="jne70066-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Patients' characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Patient</th><th align="left" valign="bottom" rowspan="1" colspan="1">Age (y) at time of IPSS</th><th align="left" valign="bottom" rowspan="1" colspan="1">Sex</th><th align="left" valign="bottom" rowspan="1" colspan="1">Peak basal (<italic toggle="yes">t</italic>
<sub>0</sub>) unadjusted ACTH ratio</th><th align="left" valign="bottom" rowspan="1" colspan="1">Peak unadjusted ACTH ratio post&#8208;CRH</th><th align="left" valign="bottom" rowspan="1" colspan="1">Pituitary&#8208;MRI result</th><th align="left" valign="bottom" rowspan="1" colspan="1">Postoperative biochemical remission for at least 1&#8201;year</th><th align="left" valign="bottom" rowspan="1" colspan="1">Confirmed by pathology examination</th><th align="left" valign="bottom" rowspan="1" colspan="1">Diagnosis</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">36</td><td align="left" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">4.9</td><td align="left" valign="top" rowspan="1" colspan="1">7.3</td><td align="left" valign="top" rowspan="1" colspan="1">No adenoma</td><td align="left" valign="top" rowspan="1" colspan="1">Indeterminate</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Pituitary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">41</td><td align="left" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">49.2</td><td align="left" valign="top" rowspan="1" colspan="1">117.1</td><td align="left" valign="top" rowspan="1" colspan="1">Adenoma &lt;6&#8201;mm</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Pituitary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">63</td><td align="left" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">8.4</td><td align="left" valign="top" rowspan="1" colspan="1">33.4</td><td align="left" valign="top" rowspan="1" colspan="1">Adenoma &lt;6&#8201;mm</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Pituitary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">65</td><td align="left" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">5.9</td><td align="left" valign="top" rowspan="1" colspan="1">19.7</td><td align="left" valign="top" rowspan="1" colspan="1">No adenoma</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Pituitary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">35</td><td align="left" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">25.0</td><td align="left" valign="top" rowspan="1" colspan="1">71.2</td><td align="left" valign="top" rowspan="1" colspan="1">No adenoma</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Pituitary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">36</td><td align="left" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">5.0</td><td align="left" valign="top" rowspan="1" colspan="1">141.1</td><td align="left" valign="top" rowspan="1" colspan="1">Adenoma &lt;6&#8201;mm</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Pituitary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">58</td><td align="left" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">18.2</td><td align="left" valign="top" rowspan="1" colspan="1">282.2</td><td align="left" valign="top" rowspan="1" colspan="1">No adenoma</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Pituitary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">60</td><td align="left" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">14.8</td><td align="left" valign="top" rowspan="1" colspan="1">577.5</td><td align="left" valign="top" rowspan="1" colspan="1">Adenoma &lt;6&#8201;mm</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Pituitary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">37.7</td><td align="left" valign="top" rowspan="1" colspan="1">186.4</td><td align="left" valign="top" rowspan="1" colspan="1">No adenoma</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Pituitary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">41</td><td align="left" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">26.5</td><td align="left" valign="top" rowspan="1" colspan="1">526.7</td><td align="left" valign="top" rowspan="1" colspan="1">No adenoma</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Pituitary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="left" valign="top" rowspan="1" colspan="1">49</td><td align="left" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">33.1</td><td align="left" valign="top" rowspan="1" colspan="1">367.0</td><td align="left" valign="top" rowspan="1" colspan="1">No adenoma</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Pituitary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">49</td><td align="left" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">0.8</td><td align="left" valign="top" rowspan="1" colspan="1">2.6</td><td align="left" valign="top" rowspan="1" colspan="1">Adenoma &lt;6&#8201;mm</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Pituitary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">13 (2&#215; IPSS)</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>26 (1st IPSS)</p>
<p>28 (2nd IPSS)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>1.1 (1st IPSS)</p>
<p>10.4 (2nd IPSS)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>1.7 (1st IPSS)</p>
<p>21.6 (2nd IPSS)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">Adenoma &lt;6&#8201;mm</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Pituitary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">58</td><td align="left" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">15.8</td><td align="left" valign="top" rowspan="1" colspan="1">87.3</td><td align="left" valign="top" rowspan="1" colspan="1">No adenoma</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Pituitary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">23.0</td><td align="left" valign="top" rowspan="1" colspan="1">106.7</td><td align="left" valign="top" rowspan="1" colspan="1">Adenoma &lt;6&#8201;mm</td><td align="left" valign="top" rowspan="1" colspan="1">No<xref rid="jne70066-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Pituitary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="left" valign="top" rowspan="1" colspan="1">66</td><td align="left" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">1.2</td><td align="left" valign="top" rowspan="1" colspan="1">4.3</td><td align="left" valign="top" rowspan="1" colspan="1">Adenoma &lt;6&#8201;mm</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Pituitary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="left" valign="top" rowspan="1" colspan="1">66</td><td align="left" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">2.2</td><td align="left" valign="top" rowspan="1" colspan="1">10.2</td><td align="left" valign="top" rowspan="1" colspan="1">No adenoma</td><td align="left" valign="top" rowspan="1" colspan="1">NA<xref rid="jne70066-note-0002" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Ectopic</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">18</td><td align="left" valign="top" rowspan="1" colspan="1">60</td><td align="left" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">1.3</td><td align="left" valign="top" rowspan="1" colspan="1">2.4</td><td align="left" valign="top" rowspan="1" colspan="1">No adenoma</td><td align="left" valign="top" rowspan="1" colspan="1">NA<xref rid="jne70066-note-0002" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">NA<xref rid="jne70066-note-0003" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Ectopic</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1">67</td><td align="left" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">1.3</td><td align="left" valign="top" rowspan="1" colspan="1">1.8</td><td align="left" valign="top" rowspan="1" colspan="1">No adenoma</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Ectopic</td></tr></tbody></table><table-wrap-foot id="jne70066-ntgp-0002"><fn id="jne70066-note-0001"><label>
<sup>a</sup>
</label><p>Transsphenoidal hypophysectomy &lt;1&#8201;year.</p></fn><fn id="jne70066-note-0002"><label>
<sup>b</sup>
</label><p>Not applicable, patient had a bilateral adrenalectomy.</p></fn><fn id="jne70066-note-0003"><label>
<sup>c</sup>
</label><p>Not applicable, no pathology examination done.</p></fn></table-wrap-foot></table-wrap></sec><sec id="jne70066-sec-0013"><label>3.2</label><title>Cut&#8208;off values</title><sec id="jne70066-sec-0014"><label>3.2.1</label><title>
<styled-content style="fixed-case" toggle="no">ACTH</styled-content> ratios</title><p>ACTH ratios were calculated for each time point, and peak ratios were compared between patients with CD and EAS. No clear cut&#8208;off value diagnosed all patients. Peak ACTH ratios ranged from 1.7 to 577.5 for CD and 1.8 to 10.2 for EAS (Figure&#160;<xref rid="jne70066-fig-0002" ref-type="fig">2A&#8211;C</xref>). Using the standard cut&#8208;offs (&#8805;2.0 pre&#8208;CRH; &#8805;3.0 post&#8208;CRH),<xref rid="jne70066-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="jne70066-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> sensitivity was 88.2% (2 false negatives: cases 12, 13), and specificity was 66.7% (1 false positive: case 17) (Data&#160;<xref rid="jne70066-supitem-0001" ref-type="supplementary-material">S2</xref>).</p><fig position="float" fig-type="FIGURE" id="jne70066-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Distribution of the (unadjusted) ACTH ratios shown separately for the patients with pituitary ACTH&#8208;dependent (A) and ectopic ACTH&#8208;dependent Cushing syndrome (B). In (C) the lower section of (A) is shown, illustrating the crucial data points.</p></caption><graphic position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="JNE-37-e70066-g003.jpg"/></fig></sec><sec id="jne70066-sec-0015"><label>3.2.2</label><title>Prolactin&#8208;adjusted peak <styled-content style="fixed-case" toggle="no">ACTH</styled-content> ratios</title><p>Prolactin adjustment allowed clear discrimination between CD and EAS. Basal prolactin&#8208;adjusted peak ACTH ratios (Method 1) were&#8201;&gt;1.5 in all patients with CD and&#8201;&lt;0.6 in all patients with EAS (Figure&#160;<xref rid="jne70066-fig-0003" ref-type="fig">3A&#8211;C</xref>). Concurrent prolactin&#8208;adjusted peak ACTH ratios (Method 2) were&#8201;&gt;1.1 for CD and&#8201;&lt;0.3 for EAS. Optimal cut&#8208;offs from ROC analysis were 1.0 (basal) and 0.7 (concurrent), both yielding 100% sensitivity and specificity (Figure&#160;<xref rid="jne70066-fig-0004" ref-type="fig">4A&#8211;C</xref>, Data&#160;<xref rid="jne70066-supitem-0001" ref-type="supplementary-material">S2</xref>). A consistent post&#8208;CRH increase in prolactin on the ACTH&#8208;dominant side (13.5&#8211;664.3%) was observed in patients with CD, influencing the adjusted ratios.</p><fig position="float" fig-type="FIGURE" id="jne70066-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Distribution of the prolactin&#8208;adjusted ACTH ratios calculated by different methods, shown separately for the patients with pituitary ACTH&#8208;dependent (A) and ectopic ACTH&#8208;dependent Cushing syndrome (B). In (C) the lower section of (A) is shown, illustrating the crucial data points; Method 1: Basal prolactin&#8208;adjusted peak ACTH ratio. Method 2: Concurrent prolactin&#8208;adjusted peak ACTH ratio. Method 3: Basal prolactin&#8208;adjusted ACTH ratio. Method 4: Concurrent prolactin&#8208;adjusted ACTH ratio.</p></caption><graphic position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="JNE-37-e70066-g001.jpg"/></fig><fig position="float" fig-type="FIGURE" id="jne70066-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Receiver operating characteristic (ROC) curve for unadjusted ACTH ratios (A), basal prolactin&#8208;adjusted peak ACTH ratios (B) and concurrent prolactin&#8208;adjusted peak ACTH ratios (C).</p></caption><graphic position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="JNE-37-e70066-g004.jpg"/></fig></sec></sec><sec id="jne70066-sec-0016"><label>3.3</label><title>Preference for adjustment based on peak <styled-content style="fixed-case" toggle="no">ACTH</styled-content> ratio</title><p>Adjusting all time&#8208;point ACTH ratios and selecting the peak prolactin&#8208;adjusted ratio (Methods 3 and 4) failed to discriminate CD from EAS (Figure&#160;<xref rid="jne70066-fig-0003" ref-type="fig">3A&#8211;C</xref>).</p></sec><sec id="jne70066-sec-0017"><label>3.4</label><title>Timing of basal sample</title><p>No differences in IPSS interpretation were found when basal values at <italic toggle="yes">t</italic> &#8722; 5&#8201;min were used instead of <italic toggle="yes">t</italic>
<sub>0</sub> (Data&#160;<xref rid="jne70066-supitem-0001" ref-type="supplementary-material">S3</xref>; Table&#160;<xref rid="jne70066-supitem-0001" ref-type="supplementary-material">S1</xref>).</p></sec><sec id="jne70066-sec-0018"><label>3.5</label><title>Discrepant results between unadjusted and adjusted <styled-content style="fixed-case" toggle="no">ACTH</styled-content> ratios</title><sec id="jne70066-sec-0019"><label>3.5.1</label><title>Case description patient 12</title><p>This patient was diagnosed with ACTH&#8208;dependent hypercortisolism, and the pituitary&#8208;MRI showed a right&#8208;sided microadenoma of 5&#8201;mm. In 2016, this patient underwent IPSS, resulting in all ACTH ratios &lt;2.0 pre&#8208;CRH and&#8201;&lt;3.0 post&#8208;CRH, consistent with an ectopic source. CT imaging of the thorax and abdomen showed no evidence of an ectopic source. Basal and concurrent prolactin&#8208;adjusted peak ACTH ratios were, respectively, 2.8 and 1.2. The patient did not prefer to undergo an IPSS again. An explorative transsphenoidal hypophysectomy was performed, after which the patients' symptoms were reduced. Histological examination did not confirm a pituitary source, but biochemical remission after 1&#8201;year of follow&#8208;up was established, and therefore, considered as confirmation of a pituitary origin. In addition, 8&#8201;years after surgery, the patient remains in remission.</p></sec><sec id="jne70066-sec-0020"><label>3.5.2</label><title>Case description patient 13</title><p>This patient was diagnosed with ACTH&#8208;dependent hypercortisolism, and the pituitary&#8208;MRI showed a hyperintense configuration of 5&#8201;mm in the midline of the pituitary, without a clear aspect of a microadenoma. In 2020, this patient underwent IPSS, resulting in all ACTH ratios &lt;2.0 pre&#8208;CRH and&#8201;&lt;3.0 post&#8208;CRH (all between 0.9 and 1.7), consistent with an ectopic source. PET and CT imaging of the thorax and abdomen showed no ectopic source. Inhibition of cortisol production with metyrapone was initiated, and the patient was followed up. IPSS results were reassessed by adding prolactin adjustments, which revealed a basal and concurrent prolactin&#8208;adjusted peak ACTH ratio of 1.5 and 1.1, respectively. After discontinuation of the medication, the IPSS was repeated in January 2022, which resulted in all right&#8208;sided ACTH ratios &#8805;2.0 pre&#8208;CRH and&#8201;&#8805;3.0 post&#8208;CRH (all between 7.5 and 21.6) and basal and concurrent prolactin&#8208;adjusted peak ACTH ratios of 2.7 and 4.1, respectively, consistent with a pituitary source. In 2022, the pituitary&#8208;MRI was repeated and showed a pituitary adenoma. A transsphenoidal hypophysectomy was performed, and histological examination confirmed a pituitary source. One year after surgery, the patient remains in remission, with morning cortisol of 0.07&#8201;&#956;mol/L requiring hydrocortisone substitution.</p></sec><sec id="jne70066-sec-0021"><label>3.5.3</label><title>Case description patient 17</title><p>This patient was diagnosed with ACTH&#8208;dependent hypercortisolism, and the pituitary&#8208;MRI showed no adenoma. In 2020, this patient underwent IPSS, resulting in all right&#8208;sided ACTH ratios &#8805;2.0 pre&#8208;CRH and&#8201;&#8805;3.0 post&#8208;CRH, consistent with a pituitary source. Basal and concurrent prolactin&#8208;adjusted peak ACTH ratios were, respectively, 0.5 and 0.1, consistent with an ectopic source (Data&#160;<xref rid="jne70066-supitem-0001" ref-type="supplementary-material">S4</xref>; Figure&#160;<xref rid="jne70066-supitem-0001" ref-type="supplementary-material">S1</xref>). The patient underwent a transsphenoidal hypophysectomy; however, no histological evidence was found for an ACTH&#8208;producing pituitary adenoma. Hypercortisolemia persisted after the pituitary surgery, and therefore, a bilateral adrenalectomy was performed. Six months later, a neuroendocrine lung tumor was discovered. Histological examination showed a small number of ACTH&#8208;producing cells in this neuroendocrine lung tumor, considered as confirmation of an ectopic origin.</p></sec></sec><sec id="jne70066-sec-0022"><label>3.6</label><title>Patient with <styled-content style="fixed-case" toggle="no">EAS</styled-content> without confirmed source</title><sec id="jne70066-sec-0023"><label>3.6.1</label><title>Case description patient 18</title><p>This patient was diagnosed with ACTH&#8208;dependent hypercortisolism and had a pituitary&#8208;MRI showing no adenoma. In 2017, this patient underwent IPSS, resulting in all ACTH ratios &lt;2.0 pre&#8208;CRH and&#8201;&lt;3.0 post&#8208;CRH, consistent with an ectopic source. Basal and concurrent prolactin&#8208;adjusted peak ACTH ratios were, respectively, 0.6 and 0.3, consistent with an ectopic source. CT imaging of the thorax and abdomen showed no evidence of an ectopic ACTH source. Medical treatment of the endogenous hypercortisolism was initiated, along with active follow&#8208;up. A Ga&#8208;68&#8208;DOTA&#8208;TOC PET/CT was performed and showed a focus in the sphenoid bone suspicious for an intra&#8208;osseous meningioma. An ACTH&#8208;producing meningioma is rare but is described in the literature.<xref rid="jne70066-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="jne70066-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Due to increasing clinical symptoms of hypercortisolism despite medical treatment and the remaining uncertainty about the source of ACTH production, a bilateral adrenalectomy was performed. It remains unclear whether, in this patient, the meningioma is the source of ectopic ACTH production or not. Repeated imaging during follow&#8208;up, however, showed no other abnormalities suspicious for a neuroendocrine tumor, and at follow&#8208;up imaging, the meningioma remained stable.</p></sec></sec><sec id="jne70066-sec-0024"><label>3.7</label><title>Single&#8208;point diagnostic accuracy</title><p>When only CRH&#8208;stimulated cases with confirmed CD were considered (<italic toggle="yes">n</italic>&#8201;=&#8201;17), the single&#8208;point diagnostic accuracy using unadjusted ACTH ratios was 82.4% (14/17), 82.4% (14/17), 88.2% (15/17), 70.6% (12/17), 76.5% (13/17), 76.5% (13/17), and 88.2% (15/17) for the <italic toggle="yes">t</italic>&#8201;&#8722;&#8201;5, <italic toggle="yes">t</italic>
<sub>0</sub>, <italic toggle="yes">t</italic>&#8201;+&#8201;1&#189;, <italic toggle="yes">t</italic>&#8201;+&#8201;5, <italic toggle="yes">t</italic>&#8201;+&#8201;10, <italic toggle="yes">t</italic>&#8201;+&#8201;15, and <italic toggle="yes">t</italic>&#8201;+&#8201;20 time points, respectively. Since two patients failed to demonstrate positive unadjusted ACTH ratios at all time points (two false&#8208;negative patients), maximal diagnostic accuracy was achieved within the first 90&#8201;s (+1&#189;&#8201;min) after stimulation.</p></sec><sec id="jne70066-sec-0025"><label>3.8</label><title>Additional analysis: <styled-content style="fixed-case" toggle="no">DDAVP</styled-content>&#8208;stimulated <styled-content style="fixed-case" toggle="no">IPSS</styled-content> procedures</title><p>Five of six DDAVP&#8208;stimulated patients had pathology and/or remission&#8208;confirmed CD (age 53&#8201;&#177;&#8201;18&#8201;years; 4 women). Two patients with unadjusted ACTH ratios &lt;2.0 pre&#8208;CRH and&#8201;&lt;3.0 post&#8208;CRH were misdiagnosed with EAS. Basal prolactin&#8208;adjusted ratios (Method 1) &gt;1.3 and concurrent ratios (Method 2) &gt;0.6 correctly identified all CD cases. One patient without pathology&#8208;confirmed source had unadjusted ACTH ratios &#8805;2.0 pre&#8208;CRH and&#8201;&#8805;3.0 post&#8208;CRH, with adjusted ratios of 3.7 (basal) and 3.0 (concurrent).</p></sec></sec><sec sec-type="discussion" id="jne70066-sec-0026"><label>4</label><title>DISCUSSION</title><p>The differentiation between EAS and CD by IPSS is challenging but essential to tailor therapy. This retrospective study found that prolactin&#8208;adjusted ACTH ratios, using both basal and concurrent prolactin concentrations and the methods described in literature,<xref rid="jne70066-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="jne70066-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> improved diagnostic accuracy compared with unadjusted ratios. By including all consecutive patients undergoing IPSS during the study period, the risk of selection bias was minimized. Moreover, we are able to provide an extensive elaboration of the prolactin&#8208;adjusted ACTH ratios of patients followed during a long period of time, and of the various formulas that can be used to calculate these ratios. We assessed the validity of the results and cut&#8208;off values described in previously performed studies and assessed new methods of prolactin adjustments.</p><p>In our cohort, all patients with CD showed basal prolactin&#8208;adjusted peak ACTH ratios &gt;1.5, and all patients with EAS &lt;0.6. Concurrent prolactin&#8208;adjusted peak ACTH ratios were&#8201;&gt;1.1 in all patients with CD and&#8201;&lt;0.3 in all patients with EAS. In the literature various cut&#8208;off values for prolactin&#8208;adjusted peak ACTH ratios to differentiate between CD and EAS are described. The most commonly used are those of Findling et al., using basal prolactin&#8208;adjusted peak ACTH ratios &gt;0.8 to indicate CD and ratios &lt;0.6 to indicate EAS; and Sharma et al., using basal prolactin&#8208;adjusted peak ACTH ratios &#8805;1.3 to indicate CD and ratios &#8804;0.7 to indicate EAS<xref rid="jne70066-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="jne70066-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> (Table&#160;<xref rid="jne70066-tbl-0002" ref-type="table">2</xref>). Our study results support the validity of these previously established cut&#8208;off values. In the present study, the optimal cut&#8208;off values for basal prolactin&#8208;adjusted ACTH ratios (Method 1) and concurrent prolactin&#8208;adjusted ACTH ratios (Method 2) differ, and therefore, cut&#8208;off values cannot be used interchangeably. The prolactin&#8208;adjusted peak ACTH ratios and the reference discriminative values should be interpreted with caution and in clinical context, given the limited size of the present cohort.</p><table-wrap position="float" id="jne70066-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Overview of studies and their used cut&#8208;off values and methods to calculate the prolactin&#8208;adjusted peak ACTH ratios.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Study</th><th align="left" valign="bottom" rowspan="1" colspan="1">Number of patients</th><th align="left" valign="bottom" rowspan="1" colspan="1">Confirmed by pathology and/or remission after surgery</th><th align="left" valign="bottom" rowspan="1" colspan="1">Pituitary&#8208;MRI performed</th><th align="left" valign="bottom" rowspan="1" colspan="1">Stimulation method</th><th align="left" valign="bottom" rowspan="1" colspan="1">Used calculations and cut&#8208;off values</th><th align="left" valign="bottom" rowspan="1" colspan="1">Results</th><th align="left" valign="bottom" rowspan="1" colspan="1">Optimal (new) cut&#8208;off value in study</th></tr></thead><tbody valign="top"><tr><td rowspan="2" align="left" valign="top" colspan="1">Findling et al. (2004)<xref rid="jne70066-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>47 CD<xref rid="jne70066-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</p>
<p>5 EAS</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">Yes</td><td rowspan="2" align="left" valign="top" colspan="1">Yes<xref rid="jne70066-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td rowspan="2" align="left" valign="top" colspan="1">CRH</td><td align="left" valign="top" rowspan="1" colspan="1">Peak ACTH ratio of &gt;2.0 pre&#8208;CRH and/or &gt;3.0 post&#8208;CRH indicating CD.</td><td align="left" valign="top" rowspan="1" colspan="1">Using peak post&#8208;CRH ACTH ratio resulted in 44 TP (&gt;4.8), 5 TN (&lt;2.2), and 3 FN (1.2&#8211;2.7).</td><td rowspan="2" align="left" valign="top" colspan="1">Basal prolactin&#8208;adjusted peak ACTH ratio&#8201;&gt;0.8 indicating CD and&#8201;&lt;0.6 indicating EAS.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Basal prolactin&#8208;adjusted peak ACTH ratio&#8201;&gt;0.8 indicating CD and&#8201;&lt;0.6 indicating EAS.</td><td align="left" valign="top" rowspan="1" colspan="1">Using basal prolactin&#8208;adjusted peak ACTH ratios resulted in 47 TP (&gt;0.8) and 5 TN (&lt;0.6).</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Sharma et al. (2011)<xref rid="jne70066-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>17 CD</p>
<p>8 EAS</p>
<p>4 occult<xref rid="jne70066-note-0007" ref-type="table-fn">
<sup>c</sup>
</xref>
</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">Yes</td><td rowspan="2" align="left" valign="top" colspan="1">Yes</td><td rowspan="2" align="left" valign="top" colspan="1">CRH</td><td align="left" valign="top" rowspan="1" colspan="1">Peak ACTH ratio of &#8805;2.0 pre&#8208;CRH and/or &#8805;3.0 post&#8208;CRH indicating CD.</td><td align="left" valign="top" rowspan="1" colspan="1">Using peak post&#8208;CRH ACTH ratio resulted in 16 TP, 7 TN, 1 FN (1.3), and 1 FP (9.5).</td><td rowspan="2" align="left" valign="top" colspan="1">Basal prolactin&#8208;adjusted peak ACTH ratio&#8201;&#8805;1.3 indicating CD and&#8201;&#8804;0.7 indicating EAS.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Basal prolactin&#8208;adjusted peak ACTH ratio&#8201;&gt;0.8 indicating CD and&#8201;&lt;0.6 indicating EAS.</td><td align="left" valign="top" rowspan="1" colspan="1">Using basal prolactin&#8208;adjusted peak ACTH ratio resulted in 17 TP (1.3&#8211;40.9), 6 TN (0.2&#8211;0.5), 1 FP<xref rid="jne70066-note-0008" ref-type="table-fn">
<sup>d</sup>
</xref> (5.6), and 1 indeterminate (0.7).</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Grant et al. (2012)<xref rid="jne70066-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>72 CD</p>
<p>10 EAS</p>
<p>1 indeterminate<xref rid="jne70066-note-0009" ref-type="table-fn">
<sup>e</sup>
</xref>
</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">Yes</td><td rowspan="2" align="left" valign="top" colspan="1">&#8212;</td><td rowspan="2" align="left" valign="top" colspan="1">CRH</td><td align="left" valign="top" rowspan="1" colspan="1">Peak ACTH ratio of &gt;2.0 pre&#8208;CRH and/or &gt;3.0 post&#8208;CRH indicating CD.</td><td align="left" valign="top" rowspan="1" colspan="1">Using peak post&#8208;CRH ACTH ratio resulted in 66 TP, 10 TN<xref rid="jne70066-note-0010" ref-type="table-fn">
<sup>f</sup>
</xref>, 6 FN, and 1 FP.</td><td rowspan="2" align="left" valign="top" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Basal prolactin&#8208;adjusted peak ACTH ratio&#8201;&gt;0.8 indicating CD and&#8201;&lt;0.6 indicating EAS.</td><td align="left" valign="top" rowspan="1" colspan="1">Using basal prolactin&#8208;adjusted peak ACTH ratio resulted in 72 TP, 10 TN, and 1 FP.</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Qiao et al. (2015)<xref rid="jne70066-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>38 CD</p>
<p>2 occult<xref rid="jne70066-note-0011" ref-type="table-fn">
<sup>g</sup>
</xref>
</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">Yes</td><td rowspan="2" align="left" valign="top" colspan="1">Yes</td><td rowspan="2" align="left" valign="top" colspan="1">DDAVP</td><td align="left" valign="top" rowspan="1" colspan="1">Peak ACTH ratio of &#8805;2.0 pre&#8208;DDAVP and/or &#8805;3.0 post&#8208;DDAVP indicating CD.</td><td align="left" valign="top" rowspan="1" colspan="1">Using peak post&#8208;DDAVP ACTH ratio resulted in 35 TP and 3 FN.</td><td rowspan="2" align="left" valign="top" colspan="1">Concurrent prolactin&#8208;adjusted peak ACTH ratio&#8201;&#8805;1.2 indicating CD.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Concurrent prolactin&#8208;adjusted peak ACTH ratio&#8201;&gt;0.8 indicating CD and&#8201;&lt;0.6 indicating EAS.</td><td align="left" valign="top" rowspan="1" colspan="1">Using concurrent prolactin&#8208;adjusted peak ACTH ratio resulted in 38 TP.</td></tr><tr><td rowspan="4" align="left" valign="top" colspan="1">De Sousa et al. (2017)<xref rid="jne70066-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>
</td><td rowspan="4" align="left" valign="top" colspan="1">13 CD</td><td rowspan="4" align="left" valign="top" colspan="1">In 9 out of 13</td><td rowspan="4" align="left" valign="top" colspan="1">Yes</td><td rowspan="4" align="left" valign="top" colspan="1">CRH</td><td align="left" valign="top" rowspan="1" colspan="1">ACTH ratios of &#8805;2.0 pre&#8208;CRH and&#8201;&#8805;3.0 post&#8208;CRH indicating CD.</td><td align="left" valign="top" rowspan="1" colspan="1">Using ACTH ratios pre&#8208; and post&#8208;CRH resulted in 13 TP.</td><td rowspan="4" align="left" valign="top" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Basal prolactin&#8208;adjusted peak ACTH ratio&#8201;&gt;0.8 indicating CD and&#8201;&lt;0.6 indicating EAS.</td><td align="left" valign="top" rowspan="1" colspan="1">Using basal prolactin&#8208;adjusted peak ACTH ratio resulted in 13 TP.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Basal prolactin&#8208;adjusted peak ACTH ratio&#8201;&#8805;1,3 indicating CD and&#8201;&#8804;0.7 indicating EAS.</td><td align="left" valign="top" rowspan="1" colspan="1">Using basal prolactin&#8208;adjusted peak ACTH ratio resulted in 11 TP diagnoses and 2 indeterminate results.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Concurrent prolactin&#8208;adjusted peak ACTH ratio&#8201;&gt;0.8 indicating CD and&#8201;&lt;0.6 indicating EAS.</td><td align="left" valign="top" rowspan="1" colspan="1">Using concurrent prolactin&#8208;adjusted peak ACTH ratio resulted in 13 TP.</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Akbari et al. (2020)<xref rid="jne70066-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>15 CD</p>
<p>5 EAS</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">Yes</td><td rowspan="2" align="left" valign="top" colspan="1">Yes</td><td rowspan="2" align="left" valign="top" colspan="1">DDAVP</td><td align="left" valign="top" rowspan="1" colspan="1">ACTH ratio of &#8805;2.0 pre&#8208;DDAVP and peak ACTH ratio&#8201;&#8805;3.0 post&#8208;DDAVP indicating CD.</td><td align="left" valign="top" rowspan="1" colspan="1">Using ACTH ratios pre&#8208;DDAVP resulted in 12 TP, 5 TN, and 3 FN. Using ACTH ratios post&#8208;DDAVP resulted in 13 TP, 5 TN, and 2 FN diagnoses.</td><td rowspan="2" align="left" valign="top" colspan="1">ACTH ratio of &#8805;1.76 pre&#8208;DDAVP and&#8201;&#8805;3.9 post&#8208;DDAVP indicating CD. Concurrent prolactin&#8208;adjusted peak ACTH ratio&#8201;&#8805;0.33 indicating CD.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Concurrent prolactin&#8208;adjusted peak ACTH ratio&#8201;&#8805;0.8 indicating CD and&#8201;&lt;0.8 indicating EAS.</td><td align="left" valign="top" rowspan="1" colspan="1">Using concurrent prolactin&#8208;adjusted peak ACTH ratio resulted in 13 TP, 4 TN, 2 FN, and 1 FP.</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Apaydin et al. (2022)<xref rid="jne70066-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>49 CD</p>
<p>1 EAS</p>
<p>1 with adrenal adenomas<xref rid="jne70066-note-0012" ref-type="table-fn">
<sup>h</sup>
</xref>
</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">Yes</td><td rowspan="2" align="left" valign="top" colspan="1">Yes</td><td rowspan="2" align="left" valign="top" colspan="1">CRH</td><td align="left" valign="top" rowspan="1" colspan="1">Peak ACTH ratio of &gt;2.0 pre&#8208;CRH and/or &gt;3.0 post&#8208;CRH indicating CD.</td><td align="left" valign="top" rowspan="1" colspan="1">Using ACTH ratios pre&#8208;CRH resulted in 47 TP, 1 TN, and 2 FN. Using ACTH ratios post&#8208;CRH resulted in 49 TP and 1 TN. The patient with adrenal adenomas had pre&#8208;CRH ACTH ratios &lt;2.0 and post&#8208;CRH ACTH ratios &lt;3.0.</td><td rowspan="2" align="left" valign="top" colspan="1">Basal prolactin&#8208;adjusted peak ACTH ratio&#8201;&gt;1.3 indicating CD and&#8201;&lt;0.7 indicating EAS.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Basal prolactin&#8208;adjusted peak ACTH ratio&#8201;&gt;0.8 indicating CD.</td><td align="left" valign="top" rowspan="1" colspan="1">Using basal prolactin&#8208;adjusted peak ACTH ratio resulted in 49 TP (&gt;1.3) and 1 TN (0.7). The patient with adrenal adenomas had a basal prolactin&#8208;adjusted peak ACTH ratio of 0.9.</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Detomas et al. (2023)<xref rid="jne70066-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>25 CD</p>
<p>7 EAS</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">Yes</td><td rowspan="2" align="left" valign="top" colspan="1">Yes</td><td rowspan="2" align="left" valign="top" colspan="1">CRH</td><td align="left" valign="top" rowspan="1" colspan="1">Peak ACTH ratio of &#8805;2.0 pre&#8208;CRH and/or &#8805;3.0 post&#8208;CRH indicating CD.</td><td align="left" valign="top" rowspan="1" colspan="1">Using ACTH ratios post&#8208;CRH resulted in 22 TP, 7 TN, and 3 FN.</td><td rowspan="2" align="left" valign="top" colspan="1">ACTH ratio of &#8805;1.9 pre&#8208;CRH and&#8201;&#8805;2.1 post&#8208;CRH indicating CD. Basal prolactin&#8208;adjusted peak ACTH ratio&#8201;&#8805;1.4 indicating CD.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Basal prolactin&#8208;adjusted peak ACTH ratio&#8201;&#8805;1,3 indicating CD and&#8201;&#8804;0.7 indicating EAS.</td><td align="left" valign="top" rowspan="1" colspan="1">Using basal prolactin&#8208;adjusted peak ACTH ratio resulted in 24 TP, 4 TN, 1 FP (1.3), and 3 indeterminate.</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Ardakani et al. (2023)<xref rid="jne70066-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>8 CD</p>
<p>3 EAS</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">Yes, except one EAS<xref rid="jne70066-note-0013" ref-type="table-fn">
<sup>i</sup>
</xref>
</td><td rowspan="2" align="left" valign="top" colspan="1">Yes</td><td rowspan="2" align="left" valign="top" colspan="1">DDAVP</td><td align="left" valign="top" rowspan="1" colspan="1">Peak ACTH ratio of &#8805;2.0 pre&#8208;DDAVP and/or &#8805;3.0 post&#8208;DDAVP indicating CD.</td><td align="left" valign="top" rowspan="1" colspan="1">Using ACTH ratios pre&#8208;DDAVP resulted in 7 TP, 3 TN, and 1 FN. Using ACTH ratios post&#8208;DDAVP resulted in 8 TP and 3 TN.</td><td rowspan="2" align="left" valign="top" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Concurrent prolactin&#8208;adjusted peak ACTH ratio&#8201;&#8805;1.3 indicating CD and&#8201;&#8804;0.7 indicating EAS.</td><td align="left" valign="top" rowspan="1" colspan="1">Using concurrent prolactin&#8208;adjusted peak ACTH ratio resulted in 8 TP and 3 TN.</td></tr><tr><td rowspan="5" align="left" valign="top" colspan="1">Sprenkeler et al. (2025)</td><td rowspan="5" align="left" valign="top" colspan="1">
<p>16 CD<xref rid="jne70066-note-0014" ref-type="table-fn">
<sup>j</sup>
</xref>
</p>
<p>3 EAS<xref rid="jne70066-note-0015" ref-type="table-fn">
<sup>k</sup>
</xref>
</p>
</td><td rowspan="5" align="left" valign="top" colspan="1">Yes</td><td rowspan="5" align="left" valign="top" colspan="1">Yes</td><td rowspan="5" align="left" valign="top" colspan="1">CRH</td><td align="left" valign="top" rowspan="1" colspan="1">Peak ACTH ratio of &#8805;2.0 pre&#8208;CRH and/or&#8201;&#8805;3.0 post&#8208;CRH indicating CD.</td><td align="left" valign="top" rowspan="1" colspan="1">Using peak ACTH ratios pre&#8208; and post&#8208;CRH resulted in 15 TP, 2 TN, 2 FN, and 1 FP.</td><td rowspan="5" align="left" valign="top" colspan="1">Basal prolactin&#8208;adjusted peak ACTH ratio&#8201;&gt;1.5 indicating CD and&#8201;&lt;0.6 indicating EAS. Concurrent prolactin&#8208;adjusted peak ACTH ratio&#8201;&gt;1.1 indicating CD and&#8201;&lt;0.3 indicating EAS.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Basal prolactin&#8208;adjusted peak ACTH ratio&#8201;&gt;0.8 indicating CD and&#8201;&lt;0.6 indicating EAS.</td><td align="left" valign="top" rowspan="1" colspan="1">Using basal prolactin&#8208;adjusted peak ACTH ratio resulted in 17 TP (1.5&#8211;110.1) and 3 TN (0.3&#8211;0.6).</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Basal prolactin&#8208;adjusted peak ACTH ratio&#8201;&#8805;1.3 indicating CD and&#8201;&#8804;0.7 indicating EAS.</td><td align="left" valign="top" rowspan="1" colspan="1">Using basal prolactin&#8208;adjusted peak ACTH ratio resulted in 17 TP (1.5&#8211;110.1) and 3 TN (0.3&#8211;0.6).</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Concurrent prolactin&#8208;adjusted peak ACTH ratio&#8201;&gt;0.8 indicating CD and&#8201;&lt;0.6 indicating EAS.</td><td align="left" valign="top" rowspan="1" colspan="1">Using concurrent prolactin&#8208;adjusted peak ACTH ratio resulted in 17 TP (1.1&#8211;61.3) and 3 TN (0.1&#8211;0.3).</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Concurrent prolactin&#8208;adjusted peak ACTH ratio&#8201;&#8805;1.3 indicating CD and&#8201;&#8804;0.7 indicating EAS.</td><td align="left" valign="top" rowspan="1" colspan="1">Using concurrent prolactin&#8208;adjusted peak ACTH ratio resulted in 15 TP (1.5&#8211;61.3), 3 TN (0.1&#8211;0.3), and 2 indeterminate (1.1 and 1.2).</td></tr></tbody></table><table-wrap-foot id="jne70066-ntgp-0003"><fn id="jne70066-note-0004"><p>
<italic toggle="yes">Note</italic>: Adapted from Ref. [<xref rid="jne70066-bib-0020" ref-type="bibr">20</xref>].</p></fn><fn id="jne70066-note-0005"><label>
<sup>a</sup>
</label><p>Three of whom are index cases.</p></fn><fn id="jne70066-note-0006"><label>
<sup>b</sup>
</label><p>Only described for the three index cases.</p></fn><fn id="jne70066-note-0007"><label>
<sup>c</sup>
</label><p>Occult: IPSS results suggested EAS but the source could not be localized. These four occult cases were excluded from the analysis.</p></fn><fn id="jne70066-note-0008"><label>
<sup>d</sup>
</label><p>Patient with cyclic Cushing syndrome in whom the catheterization was performed when she was eucortisolemic.</p></fn><fn id="jne70066-note-0009"><label>
<sup>e</sup>
</label><p>This patient had only a partial biochemical cure after three transsphenoidal pituitary surgeries followed by radiotherapy treatment. A pituitary source could not be confirmed with pathology. This patient is included in the analysis.</p></fn><fn id="jne70066-note-0010"><label>
<sup>f</sup>
</label><p>One of whom had cyclical Cushing syndrome.</p></fn><fn id="jne70066-note-0011"><label>
<sup>g</sup>
</label><p>These two patients did not undergo surgical exploration; final diagnosis remained unknown. They were excluded from analysis.</p></fn><fn id="jne70066-note-0012"><label>
<sup>h</sup>
</label><p>This patient had a 6 mm pituitary adenoma and bilateral adrenal adenomas. Adrenal venous sampling indicated lateralization to the right adrenal gland. Right adrenalectomy was performed, after which remission was achieved.</p></fn><fn id="jne70066-note-0013"><label>
<sup>i</sup>
</label><p>This patient did not undergo surgery, and the diagnosis was made based on the biochemical test results. This patient is included in the analysis.</p></fn><fn id="jne70066-note-0014"><label>
<sup>j</sup>
</label><p>One of these patients has undergone the IPSS procedure twice, leading to 20 IPSS procedures included for the analysis.</p></fn><fn id="jne70066-note-0015"><label>
<sup>k</sup>
</label><p>In one of these patients, it remains unclear whether a meningioma is the source of ACTH production or not.</p></fn></table-wrap-foot></table-wrap><p>Table&#160;<xref rid="jne70066-tbl-0002" ref-type="table">2</xref> summarizes previously published results on prolactin adjustment during IPSS, including the adjustment methods and cut&#8208;off values used. A significant heterogeneity is observed among the studies, leading to difficulties in comparing study results and assessing optimal cut&#8208;off values. Most studies confirmed the presence of an ACTH&#8208;producing source by pathology and/or remission after surgery; however, some studies included patients in whom the ACTH&#8208;producing source could not be confirmed according to this gold standard. Out of nine studies, three used DDAVP and the remaining six used CRH for stimulation. In five studies, prolactin&#8208;adjusted peak ACTH ratios were calculated using basal prolactin, whereas in three other studies concurrent prolactin was used. De Sousa et al. calculated both basal and concurrent prolactin&#8208;adjusted peak ACTH ratios. To enhance the reliability of conclusions and the generalizability of optimal cut&#8208;off values in future analyses, standardization of study protocols is crucial.</p><p>Contrasting results are described about the potential added diagnostic value of using prolactin during IPSS. Most studies showed an improved diagnostic value when using prolactin&#8208;adjusted peak ACTH ratios.<xref rid="jne70066-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="jne70066-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="jne70066-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Lyu et al. recently published a meta&#8208;analysis, in which a total of 10 studies were included, showing a statistically significant improvement in sensitivity to diagnose CD when prolactin adjustments were used in IPSS compared with IPSS without prolactin adjustments.<xref rid="jne70066-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> In this meta&#8208;analysis, both calculation Methods 1 and 2 used in our study have been included in the analysis. In accordance with most of the earlier reports,<xref rid="jne70066-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="jne70066-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="jne70066-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="jne70066-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="jne70066-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> our study confirmed the added diagnostic value of prolactin measurement during IPSS when basal (Method 1) and concurrent (Method 2) prolactin&#8208;adjusted peak ACTH ratios were used. In addition to previously published studies, in our study, we examined new calculation methods including adjusting all individual ACTH ratios and then selecting the peak prolactin&#8208;adjusted ACTH ratio (Methods 3 and 4). In contrast to adjusting only the peak ACTH ratio (Methods 1 and 2), these new strategies (Methods 3 and 4) failed to distinguish between patients with CD and patients with EAS and are therefore not recommended.</p><p>It has been suggested that corrections of ACTH ratios with prolactin concentration only have additive diagnostic value when no clear elevated ACTH ratios (&lt;2.0 pre&#8208;CRH and&#8201;&lt;3.0 post&#8208;CRH) are demonstrated.<xref rid="jne70066-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="jne70066-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> In the meta&#8208;analysis by Lyu et al., an increased sensitivity but no statistically significant difference in specificity was demonstrated when prolactin&#8208;adjusted peak ACTH ratios were used compared with non&#8208;adjusted ACTH ratios.<xref rid="jne70066-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Our study showed a better diagnostic accuracy of the IPSS when prolactin&#8208;adjusted ACTH ratios were used; we showed an increased sensitivity and specificity.</p><p>The study's main limitation is its small sample size, consistent with other studies given the rarity of Cushing syndrome and limited use of IPSS. We confirmed CD in all cases through pathology or biochemical remission and EAS in two cases through pathology. The ectopic source in one patient with EAS remains unconfirmed, a limitation we acknowledge. Peripheral prolactin levels documented before IPSS were not available for 2 patients, thereby limiting our ability to assess the presence of hyperprolactinemia in these patients. They did not show clinical features suggestive of hyperprolactinemia. One must also be cautious with the interpretation of the prolactin&#8208;adjusted ACTH ratios of these procedures in patients with high prolactin concentrations, as they could potentially be influenced by the presence of hyperprolactinemia.</p><p>During the first IPSS of patient 13, ACTH ratios were&#8201;&lt;2.0 pre&#8208;CRH and&#8201;&lt;3.0 post&#8208;CRH, whereas during the second IPSS, ACTH ratios were&#8201;&#8805;2.0 pre&#8208;CRH and&#8201;&#8805;3.0 post&#8208;CRH. Given that this patient developed higher cortisol levels during the 2&#8201;years between both procedures, the observed increase in ACTH ratios is likely related to biochemical disease progression.</p><p>Differences in optimal cut&#8208;off values between basal and concurrent prolactin&#8208;adjusted ACTH ratios can be attributed to displacement of the catheter during the IPSS procedure and/or CRH stimulation of prolactin. In this study, stimulation of prolactin by CRH is seen. This finding is in line with other studies.<xref rid="jne70066-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="jne70066-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="jne70066-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="jne70066-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="jne70066-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> Findling et al. showed a greater than 10% increase in prolactin levels in the dominant petrosal sinus in 21 out of 44 patients with CD after CRH was administered. Qiao et al. described that stimulation with DDAVP did not increase the prolactin values significantly in their study.<xref rid="jne70066-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Table&#160;<xref rid="jne70066-tbl-0002" ref-type="table">2</xref> shows that studies using DDAVP for stimulation used concurrent prolactin&#8208;adjusted ACTH ratios, while studies using CRH for stimulation used basal prolactin&#8208;adjusted ACTH ratios. The same cut&#8208;off values were used regardless of the stimulation method. More research is required to investigate the interchangeability of cut&#8208;off values between IPSS procedures with different stimulation methods. Currently, worldwide there is a lack of CRH, leading to increased use of DDAVP. De Almeida et al. investigated the use of DDAVP as a stimulant during IPSS and concluded that it can enhance the diagnostic accuracy of the procedure.<xref rid="jne70066-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
</p><p>Abdallah et al. evaluated the use of fewer sampling points during IPSS, aiming to optimize both time and cost efficiency while maintaining diagnostic accuracy. Their findings suggest that sampling with as few as two time points may provide diagnostic accuracy equivalent to that of current protocols, while potentially reducing both procedure time and associated costs.<xref rid="jne70066-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> De Almeida et al. demonstrated that 97.7% of the patients with a positive response following stimulation were already positive in the third minute, and all patients (100%) until the fifth minute.<xref rid="jne70066-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Our study showed that maximal diagnostic accuracy was achieved within the first 1&#189;&#8201;minutes after stimulation. While these findings suggest that IPSS procedures with fewer sampling time points may maintain diagnostic accuracy equivalent to conventional protocols, further prospective studies are required to validate these results.</p></sec><sec sec-type="conclusions" id="jne70066-sec-0027"><label>5</label><title>CONCLUSION</title><p>Prolactin&#8208;adjusted ACTH ratios improved the diagnostic accuracy of IPSS compared with unadjusted ratios. Adjusting ACTH ratios with prolactin, whether basal or concurrent, is recommended to enhance differentiation between CD and EAS.</p></sec><sec id="jne70066-sec-0033"><title>AUTHOR CONTRIBUTIONS</title><p>
<bold>Vera E. Sprenkeler:</bold> Conceptualization; data curation; formal analysis; investigation; methodology; resources; writing &#8211; original draft. <bold>Antonius E. van Herwaarden:</bold> Conceptualization; methodology; investigation; data curation; supervision; resources; writing &#8211; review and editing. <bold>Annenienke C. van de Ven:</bold> Methodology; writing &#8211; review and editing; data curation. <bold>Benno Kusters:</bold> Resources; writing &#8211; review and editing. <bold>Sjoerd F. M. Jenniskens:</bold> Resources; writing &#8211; review and editing. <bold>Romana T. Netea&#8208;Maier:</bold> Methodology; writing &#8211; review and editing; supervision. <bold>Joanne M. de Laat:</bold> Conceptualization; data curation; methodology; formal analysis; investigation; project administration; resources; supervision; writing &#8211; original draft.</p></sec><sec id="jne70066-sec-0029"><title>FUNDING INFORMATION</title><p>The authors have nothing to disclose.</p></sec><sec sec-type="COI-statement" id="jne70066-sec-0038"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="peer-review" id="jne70066-sec-0034"><title>PEER REVIEW</title><p>The peer review history for this article is available at <ext-link xlink:href="https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/jne.70066" ext-link-type="uri">https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/jne.70066</ext-link>.</p></sec><sec sec-type="conclusions" id="jne70066-sec-0030"><title>CONSENT</title><p>The authors have nothing to disclose.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="jne70066-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Data S1.</bold> Supporting Information.</p></caption><media xlink:href="JNE-37-e70066-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="jne70066-sec-0028"><title>ACKNOWLEDGEMENTS</title><p>The authors have nothing to disclose.</p></ack><sec sec-type="data-availability" id="jne70066-sec-0032"><title>DATA AVAILABILITY STATEMENT</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list id="jne70066-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="jne70066-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jne70066-cit-0001"><string-name name-style="western"><surname>Lacroix</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Feelders</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Stratakis</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Nieman</surname><given-names>LK</given-names></string-name>. <article-title>Cushing's syndrome</article-title>. <source>Lancet</source>. <year>2015</year>;<volume>386</volume>(<issue>9996</issue>):<fpage>913</fpage>&#8208;<lpage>927</lpage>.<pub-id pub-id-type="pmid">26004339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(14)61375-1</pub-id></mixed-citation></ref><ref id="jne70066-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jne70066-cit-0002"><string-name name-style="western"><surname>Qiao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, et al. <article-title>The value of prolactin in inferior petrosal sinus sampling with desmopressin stimulation in Cushing's disease</article-title>. <source>Endocrine</source>. <year>2015</year>;<volume>48</volume>(<issue>2</issue>):<fpage>644</fpage>&#8208;<lpage>652</lpage>.<pub-id pub-id-type="pmid">25030549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12020-014-0338-3</pub-id></mixed-citation></ref><ref id="jne70066-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jne70066-cit-0003"><string-name name-style="western"><surname>Newell&#8208;Price</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bertagna</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Grossman</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Nieman</surname><given-names>LK</given-names></string-name>. <article-title>Cushing's syndrome</article-title>. <source>Lancet</source>. <year>2006</year>;<volume>367</volume>(<issue>9522</issue>):<fpage>1605</fpage>&#8208;<lpage>1617</lpage>.<pub-id pub-id-type="pmid">16698415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(06)68699-6</pub-id></mixed-citation></ref><ref id="jne70066-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jne70066-cit-0004"><string-name name-style="western"><surname>Nieman</surname><given-names>LK</given-names></string-name>, <string-name name-style="western"><surname>Biller</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Findling</surname><given-names>JW</given-names></string-name>, et al. <article-title>The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2008</year>;<volume>93</volume>(<issue>5</issue>):<fpage>1526</fpage>&#8208;<lpage>1540</lpage>.<pub-id pub-id-type="pmid">18334580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2008-0125</pub-id><pub-id pub-id-type="pmcid">PMC2386281</pub-id></mixed-citation></ref><ref id="jne70066-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jne70066-cit-0005"><string-name name-style="western"><surname>Nieman</surname><given-names>LK</given-names></string-name>, <string-name name-style="western"><surname>Biller</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Findling</surname><given-names>JW</given-names></string-name>, et al. <article-title>Treatment of Cushing's syndrome: an endocrine society clinical practice guideline</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2015</year>;<volume>100</volume>(<issue>8</issue>):<fpage>2807</fpage>&#8208;<lpage>2831</lpage>.<pub-id pub-id-type="pmid">26222757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2015-1818</pub-id><pub-id pub-id-type="pmcid">PMC4525003</pub-id></mixed-citation></ref><ref id="jne70066-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jne70066-cit-0006"><string-name name-style="western"><surname>Perlman</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Johnston</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Hui</surname><given-names>F</given-names></string-name>, et al. <article-title>Pitfalls in performing and interpreting inferior petrosal sinus sampling: personal experience and literature review</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2021</year>;<volume>106</volume>(<issue>5</issue>):<fpage>e1953</fpage>&#8208;<lpage>e1967</lpage>.<pub-id pub-id-type="pmid">33421066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgab012</pub-id><pub-id pub-id-type="pmcid">PMC8599872</pub-id></mixed-citation></ref><ref id="jne70066-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jne70066-cit-0007"><string-name name-style="western"><surname>de Herder</surname><given-names>WW</given-names></string-name>, <string-name name-style="western"><surname>Uitterlinden</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Pieterman</surname><given-names>H</given-names></string-name>, et al. <article-title>Pituitary tumour localization in patients with Cushing's disease by magnetic resonance imaging. Is there a place for petrosal sinus sampling?</article-title><source>Clin Endocrinol (Oxf)</source>. <year>1994</year>;<volume>40</volume>(<issue>1</issue>):<fpage>87</fpage>&#8208;<lpage>92</lpage>.<pub-id pub-id-type="pmid">8306486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2265.1994.tb02448.x</pub-id></mixed-citation></ref><ref id="jne70066-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jne70066-cit-0008"><string-name name-style="western"><surname>Fleseriu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Auchus</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bancos</surname><given-names>I</given-names></string-name>, et al. <article-title>Consensus on diagnosis and management of Cushing's disease: a guideline update</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2021</year>;<volume>9</volume>(<issue>12</issue>):<fpage>847</fpage>&#8208;<lpage>875</lpage>.<pub-id pub-id-type="pmid">34687601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(21)00235-7</pub-id><pub-id pub-id-type="pmcid">PMC8743006</pub-id></mixed-citation></ref><ref id="jne70066-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jne70066-cit-0009"><string-name name-style="western"><surname>Findling</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Kehoe</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Raff</surname><given-names>H</given-names></string-name>. <article-title>Identification of patients with Cushing's disease with negative pituitary adrenocorticotropin gradients during inferior petrosal sinus sampling: prolactin as an index of pituitary venous effluent</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2004</year>;<volume>89</volume>(<issue>12</issue>):<fpage>6005</fpage>&#8208;<lpage>6009</lpage>.<pub-id pub-id-type="pmid">15579751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2004-1378</pub-id></mixed-citation></ref><ref id="jne70066-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jne70066-cit-0010"><string-name name-style="western"><surname>Sharma</surname><given-names>ST</given-names></string-name>, <string-name name-style="western"><surname>Raff</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Nieman</surname><given-names>LK</given-names></string-name>. <article-title>Prolactin as a marker of successful catheterization during IPSS in patients with ACTH&#8208;dependent Cushing's syndrome</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2011</year>;<volume>96</volume>(<issue>12</issue>):<fpage>3687</fpage>&#8208;<lpage>3694</lpage>.<pub-id pub-id-type="pmid">22031511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2011-2149</pub-id><pub-id pub-id-type="pmcid">PMC3232627</pub-id></mixed-citation></ref><ref id="jne70066-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jne70066-cit-0011"><string-name name-style="western"><surname>Akbari</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ghorbani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kabootari</surname><given-names>M</given-names></string-name>, et al. <article-title>Usefulness of prolactin measurement in inferior petrosal sinus sampling with desmopressin for Cushing's syndrome</article-title>. <source>Br J Neurosurg</source>. <year>2020</year>;<volume>34</volume>(<issue>3</issue>):<fpage>253</fpage>&#8208;<lpage>257</lpage>.<pub-id pub-id-type="pmid">32238018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/02688697.2020.1736263</pub-id></mixed-citation></ref><ref id="jne70066-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jne70066-cit-0012"><string-name name-style="western"><surname>Apaydin</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Yasar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Baltacioglu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Haklar</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gogas Yavuz</surname><given-names>D</given-names></string-name>. <article-title>Does concomitant prolactin measurement &#305;ncrease the accuracy of &#305;nferior petrosal sinus sampling?</article-title><source>Neuroradiology</source>. <year>2022</year>;<volume>64</volume>(<issue>7</issue>):<fpage>1411</fpage>&#8208;<lpage>1418</lpage>.<pub-id pub-id-type="pmid">35064296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00234-021-02886-6</pub-id></mixed-citation></ref><ref id="jne70066-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jne70066-cit-0013"><string-name name-style="western"><surname>Detomas</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ritzel</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nasi&#8208;Kordhishti</surname><given-names>I</given-names></string-name>, et al. <article-title>Bilateral inferior petrosal sinus sampling with human CRH stimulation in ACTH&#8208;dependent Cushing's syndrome: results from a retrospective multicenter study</article-title>. <source>Eur J Endocrinol</source>. <year>2023</year>;<volume>188</volume>:<fpage>448</fpage>&#8208;<lpage>456</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ejendo/lvad050</pub-id><pub-id pub-id-type="pmid">37200460</pub-id></mixed-citation></ref><ref id="jne70066-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jne70066-cit-0014"><string-name name-style="western"><surname>Grant</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Dworakowska</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Carroll</surname><given-names>P</given-names></string-name>. <article-title>Maximizing the accuracy of inferior petrosal sinus sampling: validation of the use of prolactin as a marker of pituitary venous effluent in the diagnosis of Cushing's disease</article-title>. <source>Clin Endocrinol (Oxf)</source>. <year>2012</year>;<volume>76</volume>(<issue>4</issue>):<fpage>555</fpage>&#8208;<lpage>559</lpage>.<pub-id pub-id-type="pmid">22017348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2265.2011.04257.x</pub-id></mixed-citation></ref><ref id="jne70066-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jne70066-cit-0015"><string-name name-style="western"><surname>De Sousa</surname><given-names>SMC</given-names></string-name>, <string-name name-style="western"><surname>McCormack</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>McGrath</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Torpy</surname><given-names>DJ</given-names></string-name>. <article-title>Prolactin correction for adequacy of petrosal sinus cannulation may diminish diagnostic accuracy in Cushing's disease</article-title>. <source>Clin Endocrinol (Oxf)</source>. <year>2017</year>;<volume>87</volume>(<issue>5</issue>):<fpage>515</fpage>&#8208;<lpage>522</lpage>.<pub-id pub-id-type="pmid">28626863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cen.13401</pub-id></mixed-citation></ref><ref id="jne70066-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jne70066-cit-0016"><string-name name-style="western"><surname>Swearingen</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Katznelson</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>K</given-names></string-name>, et al. <article-title>Diagnostic errors after inferior petrosal sinus sampling</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2004</year>;<volume>89</volume>(<issue>8</issue>):<fpage>3752</fpage>&#8208;<lpage>3763</lpage>.<pub-id pub-id-type="pmid">15292301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2003-032249</pub-id></mixed-citation></ref><ref id="jne70066-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jne70066-cit-0017"><string-name name-style="western"><surname>Zampetti</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Grossrubatscher</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Dalino Ciaramella</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Boccardi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Loli</surname><given-names>P</given-names></string-name>. <article-title>Bilateral inferior petrosal sinus sampling</article-title>. <source>Endocr Connect</source>. <year>2016</year>;<volume>5</volume>(<issue>4</issue>):<fpage>R12</fpage>&#8208;<lpage>R25</lpage>.<pub-id pub-id-type="pmid">27352844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/EC-16-0029</pub-id><pub-id pub-id-type="pmcid">PMC5002953</pub-id></mixed-citation></ref><ref id="jne70066-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jne70066-cit-0018"><string-name name-style="western"><surname>Sharma</surname><given-names>ST</given-names></string-name>, <string-name name-style="western"><surname>Nieman</surname><given-names>LK</given-names></string-name>. <article-title>Is prolactin measurement of value during inferior petrosal sinus sampling in patients with adrenocorticotropic hormone&#8208;dependent Cushing's syndrome?</article-title><source>J Endocrinol Invest</source>. <year>2013</year>;<volume>36</volume>(<issue>11</issue>):<fpage>1112</fpage>&#8208;<lpage>1116</lpage>.<pub-id pub-id-type="pmid">23887034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3275/9067</pub-id><pub-id pub-id-type="pmcid">PMC4187104</pub-id></mixed-citation></ref><ref id="jne70066-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jne70066-cit-0019"><string-name name-style="western"><surname>Ardakani</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Rabizadeh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yadegar</surname><given-names>A</given-names></string-name>, et al. <article-title>Bilateral inferior petrosal sinus sampling: validity, diagnostic accuracy in lateralization of pituitary microadenoma, and treatment in eleven patients with Cushing's syndrome &#8211; a single&#8208;center retrospective cohort study</article-title>. <source>BMC Endocr Disord</source>. <year>2023</year>;<volume>23</volume>(<issue>1</issue>):<fpage>232</fpage>.<pub-id pub-id-type="pmid">37872539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12902-023-01495-z</pub-id><pub-id pub-id-type="pmcid">PMC10591461</pub-id></mixed-citation></ref><ref id="jne70066-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jne70066-cit-0020"><string-name name-style="western"><surname>Lyu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>D</given-names></string-name>, et al. <article-title>Should we use prolactin adjustment in bilateral inferior petrosal sinus sampling to diagnose Cushing disease? A joint meta&#8208;analysis of head&#8208;to&#8208;head diagnostic tests accuracy studies</article-title>. <source>Endocr Pract</source>. <year>2023</year>;<volume>29</volume>(<issue>4</issue>):<fpage>254</fpage>&#8208;<lpage>259</lpage>.<pub-id pub-id-type="pmid">36649781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eprac.2023.01.008</pub-id></mixed-citation></ref><ref id="jne70066-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jne70066-cit-0021"><string-name name-style="western"><surname>Oldfield</surname><given-names>EH</given-names></string-name>, <string-name name-style="western"><surname>Doppman</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Nieman</surname><given-names>LK</given-names></string-name>, et al. <article-title>Petrosal sinus sampling with and without corticotropin&#8208;releasing hormone for the differential diagnosis of Cushing's syndrome</article-title>. <source>N Engl J Med</source>. <year>1991</year>;<volume>325</volume>(<issue>13</issue>):<fpage>897</fpage>&#8208;<lpage>905</lpage>.<pub-id pub-id-type="pmid">1652686</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM199109263251301</pub-id></mixed-citation></ref><ref id="jne70066-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jne70066-cit-0022"><string-name name-style="western"><surname>Pecori Giraldi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Terreni</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Andreotti</surname><given-names>C</given-names></string-name>, et al. <article-title>Meningioma presenting with Cushing's syndrome: an unusual clinical presentation</article-title>. <source>Ann Neurol</source>. <year>2003</year>;<volume>53</volume>(<issue>1</issue>):<fpage>138</fpage>&#8208;<lpage>142</lpage>.<pub-id pub-id-type="pmid">12509860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.10454</pub-id></mixed-citation></ref><ref id="jne70066-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jne70066-cit-0023"><string-name name-style="western"><surname>Tung</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Lan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lui</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>TC</given-names></string-name>. <article-title>Meningioma&#8208;induced Cushing's syndrome due to ectopic production of corticotropin&#8208;releasing hormone: a case study of clinical presentation</article-title>. <source>Kaohsiung J Med Sci</source>. <year>2014</year>;<volume>30</volume>(<issue>5</issue>):<fpage>260</fpage>&#8208;<lpage>261</lpage>.<pub-id pub-id-type="pmid">24751390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kjms.2013.04.010</pub-id><pub-id pub-id-type="pmcid">PMC11916560</pub-id></mixed-citation></ref><ref id="jne70066-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jne70066-cit-0024"><string-name name-style="western"><surname>Mulligan</surname><given-names>GB</given-names></string-name>, <string-name name-style="western"><surname>Eray</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Faiman</surname><given-names>C</given-names></string-name>, et al. <article-title>Reduction of false&#8208;negative results in inferior petrosal sinus sampling with simultaneous prolactin and corticotropin measurement</article-title>. <source>Endocr Pract</source>. <year>2011</year>;<volume>17</volume>(<issue>1</issue>):<fpage>33</fpage>&#8208;<lpage>40</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4158/EP10067.OR</pub-id><pub-id pub-id-type="pmid">20713347</pub-id></mixed-citation></ref><ref id="jne70066-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jne70066-cit-0025"><string-name name-style="western"><surname>Daousi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Nixon</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Javadpour</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hayden</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>MacFarlane</surname><given-names>IA</given-names></string-name>. <article-title>Inferior petrosal sinus ACTH and prolactin responses to CRH in ACTH&#8208;dependent Cushing's syndrome: a single centre experience from the United Kingdom</article-title>. <source>Pituitary</source>. <year>2010</year>;<volume>13</volume>(<issue>2</issue>):<fpage>95</fpage>&#8208;<lpage>104</lpage>.<pub-id pub-id-type="pmid">19768550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11102-009-0200-4</pub-id></mixed-citation></ref><ref id="jne70066-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jne70066-cit-0026"><string-name name-style="western"><surname>Loli</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Boccardi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Branca</surname><given-names>V</given-names></string-name>, et al. <article-title>Growth hormone and prolactin responses to corticotrophin&#8208;releasing&#8208;hormone in patients with Cushing's disease: a paracrine action of the adenomatous corticotrophic cells?</article-title><source>Clin Endocrinol (Oxf)</source>. <year>1998</year>;<volume>49</volume>(<issue>4</issue>):<fpage>433</fpage>&#8208;<lpage>439</lpage>.<pub-id pub-id-type="pmid">9876339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2265.1998.00531.x</pub-id></mixed-citation></ref><ref id="jne70066-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jne70066-cit-0027"><string-name name-style="western"><surname>de Almeida</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Rodrigues</surname><given-names>TDC</given-names></string-name>, <string-name name-style="western"><surname>Costenaro</surname><given-names>F</given-names></string-name>, et al. <article-title>Enhancing Cushing's disease diagnosis: exploring the impact of desmopressin on ACTH gradient during BIPSS</article-title>. <source>Front Endocrinol (Lausanne)</source>. <year>2023</year>;<volume>14</volume>:<elocation-id>1224001</elocation-id>.<pub-id pub-id-type="pmid">37600715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2023.1224001</pub-id><pub-id pub-id-type="pmcid">PMC10436086</pub-id></mixed-citation></ref><ref id="jne70066-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jne70066-cit-0028"><string-name name-style="western"><surname>Abdallah</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Gersey</surname><given-names>ZC</given-names></string-name>, <string-name name-style="western"><surname>Plute</surname><given-names>T</given-names></string-name>, et al. <article-title>Toward optimized and cost&#8208;efficient protocols for inferior petrosal sinus sampling in the diagnosis of Cushing disease</article-title>. <source>Neurosurgery</source>. <year>2024</year>;<volume>94</volume>(<issue>3</issue>):<fpage>508</fpage>&#8208;<lpage>514</lpage>.<pub-id pub-id-type="pmid">37706685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1227/neu.0000000000002669</pub-id></mixed-citation></ref><ref id="jne70066-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jne70066-cit-0029"><string-name name-style="western"><surname>Skrebsky de Almeida</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Martins Antunes</surname><given-names>&#193;C</given-names></string-name>, <string-name name-style="western"><surname>Czepielewski</surname><given-names>MA</given-names></string-name>. <article-title>Letter: toward optimized and cost&#8208;efficient protocols for inferior petrosal sinus sampling in the diagnosis of Cushing disease</article-title>. <source>Neurosurgery</source>. <year>2024</year>;<volume>94</volume>(<issue>3</issue>):<elocation-id>e44</elocation-id>.<pub-id pub-id-type="pmid">37982616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1227/neu.0000000000002783</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>